Radix, Ginseng Radix, Zingiberis Rhizoma and Aconiti Tuber), has been developed as a drug for chronic renal failure. In general, it is difficult to estimate the absorption and excretion of herbal medicines due to the presence of a wide variety of components. The purpose of the current study was to examine the systemic pharmacokinetics and elimination of Unpito in healthy volunteers following repeated administration as part of the clinical study of the medicine. Methods:Three compounds, (-)epicatechin 3-O-gallate (ECG), glycyrrhetic acid (GA) and rhein (RH) were selected as markers, to examine the clinical pharmacokinetics of Unpito based on their levels in this medicine. The disposition of each compound was evaluated in 24 healthy volunteers receiving multiple oral doses (4, 6, and 8 capsules three times a day). Results 
Introduction
Unpito, a Japanese traditional herbal medicine (Kampo medicine) consisting of five herbal drugs (Rhei Rhizoma, Glycyrrhizae Radix, Ginseng Radix, Zingiberis Rhizoma and Aconiti Tuber), enhances renal functions in rats displaying renal failure 1-4). Unpito has been utilized in patients with chronic renal failure 5,6).
In general, it is difficult to estimate the absorp tion and excretion of herbal medicines because of the presence of various components. We selected three compounds, i. e. epicatechin 3-O-gallate (ECG), glycyrrhetic acid (GA), and rhein (RH) as markers to examine the clinical pharmaco kinetics of Unpito based on their levels in this medicine as well as in view of their efficacy and safety. A criterion for the selection was reported in the previous paper in detail 7) .
The disposition of the marker compounds was evaluated in healthy volunteers receiving multiple oral doses (4, 6, and 8 capsules three times a day). This study was conducted as part of a phase I study of Unpito with healthy volunteers. 
Subjects
The study involved 24 healthy male volunteers receiving multiple doses. All subjects were male and their age ranged from 20 to 24 years. The body weight ranged from 48.9 to 83.1kg. The height ranged from 162.2 to 182.4cm. The subjects were in good health based on medical history and physi cal examination, including electrocardiogram and standard laboratory tests (hematology, blood chemistry, hepatitis B surface antigen, HIV antigen and urine analysis) performed prior to the study and at the end of the interval of each study. In all the subjects, there was no history or signs of pre vailing active diseases, allergies or hypersen sitivities, alcohol or drug exposure. The subjects were not allowed to consume alcohol, nicotine, caffeine or any other drugs and were advised not to undertake physical exercise or major dietary changes during the entire study period. Glycyrrhi zin (GL) is a corrigent often mixed in drugs and foods. ECG and catechins are major constituents of tea and some foods 8, 9) . Thus, foods and drinks not containg such effective compounds were selected to avoid any effects on the pharmacokinetic study of Unpito.
Study medication
TJ-8117 (Unpito) encapsulated formulation of a dry powder spray of hot water extracts from the five crude drugs was obtained from Tsumura & Co. (Tokyo, Japan). The contents of total potential ECG, RH and GA as mg equivalent are summarized in Table 1 .
Study design
In the multiple dose, randomized single blind study, each subject received 4, 6 and 8 capsules of Unpito or placebo with water three times a day, 2h prior to each meal for seven days. Each meal was served at 10:30, 14:30, and 19:30 every seven days. Vital signs (heart rate, blood pressure, respira tion) and adverse events were assessed before each drug administration and several times post admin istration. All subjects gave a written, informed consent and the protocol was approved by the independent Tsumura Protocol Review Committee and the Kitasato Institute Ethics Review Committee. 4 . Analysis of ECG, RH and GA in plasma ECG, RH and GA concentrations in the plasma from the subjects receiving Unpito were determined by the methods previously developed in our labora tories ( Table 2) , as reported in brief in the previ ous study 7). 
Data analysis
Pharmacokinetic parameters for ECG, RH and GA in the plasma were calculated using non compartmental methods by the computer program PAG-CP (Asmedica, Osaka, Japan). The measured values were directly used as maximum concentra tion in the plasma (Cmax) and the time to attain Cmax (tmax) The area under the concentration-time curve (AUC) from time zero to 24 or 48h was calculated using the trapezoidal rule. The half-life was calculated by dividing 0.693 by the absolute value of slope.
The cumulative urinary excretion ratios (% of dose) were calculated as follows:(the cumulative excretion of each compound divided by the dose of each compound estimated from the content of potential ECG, RH or GA)x100. Unpito included 0.35%, 0.55% and 0.93% potential ECG, GA and RH, respectively ( Table 2) .
The plasma concentration curves were simulated by the nonlinear least-squares regression analysis to achieve best fit with a compartment model by the computer program PAG-CP (Asmedica, Osaka, Japan). The ECG and GA plasma concentrations at each time point were lower than those simulated. On the other hand, the RH plasma concentrations were consistent with the simulation. The trough plasma concentrations of the three compounds were deter mined just prior to the first administration on Day 3, Day 5, and Day 6; as a result, the concentrations were constant and found to reach steady state. Only a slight variation of peak-trough plasma concentra tions was observed during daily administration.
The pharmacokinetic parameters of ECG, GA and RH at Day 7 after multiple dosing of Unpito are summarized in Tables 1, 2 and 3 , respectively, where they are compared with those of single dosing. Comparison of the pharmacokinetic param eters at Day 7 of multiple dosing with single dosing indicates a statistically significant difference in terms of the Cmax and AUC (0-lim) values for ECG and GA at a dose of 8 capsules. For ECG and GA, multiple dosing groups had a lower Cmax and a lower AUC (0-lim) than the single dosing group. No significant difference in the tmax and t1/2 values for ECG and GA was observed between the groups. For RH, a statistically significant difference was observed in terms of the AUC (0-lim) and t1/2 a) 4 capsules three times a day b) 6 capsules three times a day c) 8 capsules three times a day Fig The cumulative excretion ratio of VL-2 after multiple dosing of 8 capsules three times a day was lower than the ratio observed in the lower dosing.
The cumulative excretions of VL-2 for every 24h were almost invariable from Day 2 to Day 7. The excretion of VL-2 ended within 24h after the last dosing at Day 7.
The cumulative excretion ratio of RH was con stant at multiple dosing of 4,6 and 8 capsules three times a day. The cumulative excretions of RH for every 24h were almost invariable from Day 2 to Day 7. The excretion of RH ended mostly within 24 h after the last dosing at Day 7.
Since GA was not detected in urine in almost all of the subjects, except for two subjects whose cumulative excretion was 0.01% at multiple dosing of 4 capsules three times a day and one subject whose cumulative excretion was 0.01% at multiple dosing of 8 capsules three times a day.
There were 16 and 6 subjects who reported loose stool and diarrhea, respectively, as a subjective or objective symptom during this study. Since Rhei Rhizoma exerts pharmacological activities which cause diarrhea, the administration of Unpito may have relevance to the loose stool and diarrhea in the studies.
Discussion
The present study is the first report which evalu Potential accumulations of the three compounds were not observed from the roughly constant plasma concentrations of troughs at 72, 120, and 144 h after the first administration. Significant change in t1/2 was not observed between single dosing and Day 7 of multiple dosing except for RH. In the case of RH, it may likely have caused the apparent increase of t1/2 two detection points (14, 48h) which were added in the elimination phase in the multiple dose study compared with the single dose study.
Urinary excretion of VL-2 ended within 48h after the last dosing in the multiple dose study as well as in the single dose study. Because the flavan-3-ols, like ECG and other catechins were metabolized to a significant extent by ring-scission in human intesti nal bacteria 10, 11), it was suggested that the decreas ing urinary excretion ratio of VL-2 due to an increase in dose was due to a change of intestinal flora caused by an increase in dose or repeated dosing. The cumulative urinary excretion ratio of RH was constant throughout the single and multi ple studies. RH excretions in urine were ended in 24 h in almost all the subjects. GA was not detected in the urine any of the studies. The potential accumu lation any of the compounds was not indicated in these results. 
